The NHS Health Research Authority’s two-year plan to enable AI-powered innovation in health research aims to send a clear signal that the UK is moving towards a more enabling, proportionate, and innovation-friendly regulatory environment.
Principally the plan focuses on making it simpler and faster to generate the clinical evidence needed to bring new technologies to market. A key focus is clarifying what constitutes ‘research’ compared to activities such as development, evaluation, or implementation.
By updating its ‘Is my study research?’ guidance and aligning expectations around the use of AI in research processes, such as protocol development, consent, and participant materials, the HRA aims to reduce unnecessary reviews and duplication. The result should be a more streamlined approvals process, helping companies progress studies more efficiently.
The plan also places significant emphasis on improving access to data and participants. By clarifying how health data can be used – via AI-enabled and data-driven approaches – to identify and contact individuals for research, the HRA is supporting a more effective recruitment landscape. This is closely tied to national initiatives such as Secure Data Environments and the Health Data Research Service. For IVD developers, particularly those requiring large and diverse datasets to validate diagnostic performance, this could materially improve the speed, scale, and representativeness of studies.
At the same time, the HRA recognises the need for regulatory consistency and technical expertise in reviewing AI-enabled research. It will invest in building the capability of Research Ethics Committees and related bodies to ensure that assessments of AI-driven studies are informed, rigorous, and consistent. For companies, this should reduce variability in decision-making and provide greater confidence in navigating the approvals process.
Another important development is the HRA’s work to clarify data governance expectations, including the use of synthetic data. This will help companies design studies and validation approaches with a clearer understanding of acceptable data practices, reducing regulatory uncertainty.
Underlying all of these changes is a strong emphasis on maintaining public trust. The HRA is explicit that enabling AI innovation must go hand-in-hand with robust safeguards, transparency, and accountability. For members, this reinforces the importance of demonstrating strong governance, clear patient benefit, and responsible use of data within study designs.
Taken together, the plan points to a more predictable and supportive UK environment for clinical research involving AI-enabled diagnostics. Companies that engage early with these evolving expectations – particularly around study classification, data use, and recruitment pathways – will be best placed to capitalise on faster, more efficient evidence generation in the UK.
